Company intelligence / Profile preview

Dark Blue Therapeutics

Oxford, Oxfordshire, United Kingdomdarkbluetx.com ↗

Ownership: Private
Employees: ~13
Development stage: Preclinical

Overview

Dark Blue Therapeutics has not yet reported clinical results. Its lead program—an orally available small molecule degrader targeting MLLT1/3 for AML and certain solid tumors—is advancing toward first-in-human studies. The company’s pipeline includes additional preclinical programs focused on novel precision oncology targets.

Therapeutic areas: Oncology
Modalities: Small molecules (including inhibitors, degraders, glues)
Industry: Biotech

Drug pipeline

1 asset

MLLT-TPD

Preclinical

Partnerships

Collaborations with Oxford University/Oxford Science EnterprisesBristol Myers Squibb participated as an investor which may indicate partnership potential but no formal development partnership disclosed yet.

Beyond the preview

Go deeper on Dark Blue Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dark Blue Therapeutics.

Explore the full profile